Painless diagnostic and therapeutic telescopic assessment of the colon and rectum (colonoscopy) is performed at the Institute under Propofol intravenous anaesthesia, usually as a day-case procedure. With completion rates in excess of 95% and a polyp (adenoma) detection rate of 16%, the Institute offers reliable and thorough colonoscopic assessment of the colorectal patient.

Using colonoscopy as the "gold standard" colorectal investigation of choice, symptoms can be thoroughly evaluated to confirm or exclude bowel cancer. Various other non-malignant conditions including piles, polyps in the colon or rectum, inflammatory bowel disease and diverticular disease can be accurately diagnosed using colonoscopy.

Screening and surveillance protocols are followed in line with the British Society of Gastroenterology and the Association of Coloproctology of Great Britain and Ireland guidelines for colorectal cancer patients; individuals with colonic adenomas; and patients with ulcerative colitis and Crohn's disease. High risk family groups with familial adenomatous polyposis coli (FAP), hereditary non-polyposis colorectal cancer (HNPCC) and those with strong family histories of colorectal cancer are also colonoscopically surveyed by the Institute.

Colonoscopy using Propofol has proved to be a painless technique with high levels of patient satisfaction and has fewer complications than conventional sedation techniques.